Atara Biotherapeutics Inc (ATRA) CEO Isaac E. Ciechanover Sells 20,000 Shares

Atara Biotherapeutics Inc (NASDAQ:ATRA) CEO Isaac E. Ciechanover sold 20,000 shares of the business’s stock in a transaction dated Wednesday, February 14th. The shares were sold at an average price of $46.80, for a total value of $936,000.00. Following the completion of the transaction, the chief executive officer now owns 808,675 shares in the company, valued at approximately $37,845,990. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Shares of Atara Biotherapeutics Inc (NASDAQ:ATRA) traded up $3.30 during mid-day trading on Wednesday, reaching $48.35. The company had a trading volume of 1,427,869 shares, compared to its average volume of 1,256,386. The firm has a market cap of $1,480.00, a PE ratio of -13.93 and a beta of 2.71. Atara Biotherapeutics Inc has a 1 year low of $11.80 and a 1 year high of $49.90.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ATRA. SG Americas Securities LLC acquired a new position in Atara Biotherapeutics during the 3rd quarter worth approximately $142,000. Voya Investment Management LLC increased its position in Atara Biotherapeutics by 16.2% during the 2nd quarter. Voya Investment Management LLC now owns 11,813 shares of the biotechnology company’s stock worth $165,000 after purchasing an additional 1,651 shares during the period. Russell Investments Group Ltd. acquired a new position in Atara Biotherapeutics during the 3rd quarter worth approximately $170,000. The Manufacturers Life Insurance Company increased its position in Atara Biotherapeutics by 7.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 20,377 shares of the biotechnology company’s stock worth $285,000 after purchasing an additional 1,369 shares during the period. Finally, Dimensional Fund Advisors LP increased its position in Atara Biotherapeutics by 2.9% during the 2nd quarter. Dimensional Fund Advisors LP now owns 21,718 shares of the biotechnology company’s stock worth $304,000 after purchasing an additional 610 shares during the period. Institutional investors own 69.58% of the company’s stock.

Several equities analysts recently issued reports on the company. BidaskClub upgraded Atara Biotherapeutics from a “buy” rating to a “strong-buy” rating in a research report on Tuesday. Zacks Investment Research cut Atara Biotherapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, February 6th. ValuEngine upgraded Atara Biotherapeutics from a “sell” rating to a “hold” rating in a research report on Friday, December 29th. Cowen assumed coverage on Atara Biotherapeutics in a research report on Friday, January 26th. They issued an “outperform” rating on the stock. Finally, Canaccord Genuity restated a “buy” rating on shares of Atara Biotherapeutics in a research report on Thursday, November 9th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, four have issued a buy rating and one has given a strong buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $30.60.

WARNING: “Atara Biotherapeutics Inc (ATRA) CEO Isaac E. Ciechanover Sells 20,000 Shares” was reported by Markets Daily and is the sole property of of Markets Daily. If you are accessing this article on another website, it was illegally stolen and reposted in violation of US and international trademark and copyright laws. The original version of this article can be viewed at https://www.themarketsdaily.com/2018/02/15/atara-biotherapeutics-inc-atra-ceo-isaac-e-ciechanover-sells-20000-shares.html.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells.

Insider Buying and Selling by Quarter for Atara Biotherapeutics (NASDAQ:ATRA)

Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply